LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Multi‐site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos

    Nihal El Rouby / Leiliane Rodrigues Marcatto / Karla Claudio / Letícia Camargo Tavares / Heidi Steiner / Marianna R. Botton / Steve A. Lubitz / Echo N. Fallon / Kevin Yee / Justin Kaye / Stuart A. Scott / Jason Karnes / Paulo Caleb Junior de Lima Santos / Jorge Duconge / Larisa H. Cavallari

    Clinical and Translational Science, Vol 14, Iss 1, Pp 268-

    2021  Volume 276

    Abstract: We conducted a multi‐site investigation of genetic determinants of warfarin dose variability in Latinos from the U.S. and Brazil. Patients from four institutions in the United States (n = 411) and Brazil (n = 663) were genotyped for VKORC1 c.‐1639G> A, ... ...

    Abstract We conducted a multi‐site investigation of genetic determinants of warfarin dose variability in Latinos from the U.S. and Brazil. Patients from four institutions in the United States (n = 411) and Brazil (n = 663) were genotyped for VKORC1 c.‐1639G> A, common CYP2C9 variants, CYP4F2*3, and NQO1*2. Multiple regression analysis was used in the U.S. cohort to test the association between warfarin dose and genotype, adjusting for clinical factors, with further testing in an independent cohort of Brazilians. In the U.S. cohort, VKORC1 and CYP2C9 variants were associated with lower warfarin dose (β = −0.29, P < 2.0 × 10−16; β = −0.21, P = 4.7 × 10−7, respectively) whereas CYP4F2 and NQO1 variants were associated with higher dose (β = 0.10, P = 2 × 10−4; β = 0.10, P = 0.01, respectively). Associations with VKORC1 (β = −0.14, P = 2.0 × 10−16), CYP2C9 (β = −0.07, P = 5.6 × 10−10), and CYP4F2 (β = 0.03, P = 3 × 10−3), but not NQO1*2 (β = 0.01, P = 0.30), were replicated in the Brazilians, explaining 43–46% of warfarin dose variability among the cohorts from the U.S. and Brazil, respectively. We identified genetic associations with warfarin dose requirements in the largest cohort of ancestrally diverse, warfarin‐treated Latinos from the United States and Brazil to date. We confirmed the association of variants in VKORC1, CYP2C9, and CYP4F2 with warfarin dose in Latinos from the United States and Brazil.
    Keywords Therapeutics. Pharmacology ; RM1-950 ; Public aspects of medicine ; RA1-1270
    Subject code 616
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher Wiley
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Non-HFE hemochromatosis

    Paulo Caleb Júnior de Lima Santos / Carla Luana Dinardo / Rodolfo Delfini Cançado / Isolmar Tadeu Schettert / José Eduardo Krieger / Alexandre Costa Pereira

    Revista Brasileira de Hematologia e Hemoterapia, Vol 34, Iss 4, Pp 311-

    2012  Volume 316

    Abstract: Hereditary hemochromatosis (HH) is an autosomal recessive disorder classically related to HFE mutations. However, since 1996, it is known that HFE mutations explain about 80% of HH cases, with the remaining around 20% denominated non-HFE hemochromatosis. ...

    Abstract Hereditary hemochromatosis (HH) is an autosomal recessive disorder classically related to HFE mutations. However, since 1996, it is known that HFE mutations explain about 80% of HH cases, with the remaining around 20% denominated non-HFE hemochromatosis. Nowadays, four main genes are implicated in the pathophysiology of clinical syndromes classified as non-HFE hemochromatosis: hemojuvelin (HJV, type 2Ajuvenile HH), hepcidin (HAMP, type 2B juvenile HH), transferrin receptor 2 (TFR2, type 3 HH) and ferroportin (SLC40A1, type 4 HH). The aim of this review is to explore molecular, clinical and management aspects of non-HFE hemochromatosis.
    Keywords Hemochromatosis ; Iron overload ; Iron metabolism disorders ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2012-01-01T00:00:00Z
    Publisher Sociedade Brasileira de Hematologia e Hemoterapia
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: INTERFERÊNCIAS EM EXAMES LABORATORIAIS

    Daniela Hisaye KANASHIRO, Flávia Domingues GAMEIRO, Válter Luiz da COSTA JÚNIOR, Alexsandro Macedo SILVA, Luciane Maria RIBEIRO NETO, Reiko Soraya MATSUI, Sandro Jorge JANUÁRIO, Paulo Caleb Júnior de Lima SANTOS

    Infarma: Pharmaceutical Sciences, Vol 25, Iss 3, Pp 163-

    CRITÉRIO DIAGNÓSTICO PARA O DIABETES MELLITUS E PRINCIPAIS FÁRMACOS HIPOGLICEMIANTES

    2013  Volume 168

    Abstract: O diabetes mellitus (DM) está entre as principais condições crônicas de saúde. O critério diagnóstico atual para o DM propõe os seguintes testes laboratoriais: glicose plasmática em jejum, hemoglobina glicada ou glicosilada, teste oral de tolerância à ... ...

    Abstract O diabetes mellitus (DM) está entre as principais condições crônicas de saúde. O critério diagnóstico atual para o DM propõe os seguintes testes laboratoriais: glicose plasmática em jejum, hemoglobina glicada ou glicosilada, teste oral de tolerância à glicose, frutosamina, insulina, peptídeo C e glucagon. Estes exames laboratoriais podem apresentar interferências de medicamentos, sejam fisiológicas ou analíticas. Na literatura consultada foi possível identificar 30 fármacos ou grupo de fármacos que possuem evidências de interferir nos principais exames de diagnóstico da DM. Ressalta-se que praticamente na sua totalidade estes interferem nos níveis de glicemia, sendo que, 81,5% destes contribuem de forma a aumentar estes valores. Dentre estes fármacos encontram-se MIPs (medicamentos isentos de prescrição), como o paracetamol e o ácido acetilsalicílico, e anti-inflamatórios esteroidais, como a dexametasona e prednisolona, amplamente utilizados na terapêutica medicamentosa. Da mesma forma, os medicamentos empregados no tratamento de pacientes diabéticos incluído na RENAME como insulina NPH (protamina neutra Hagedorn), insulina humana regular, glibenclamida, gliclazida e cloridrato de metformina podem interferir em exames laboratoriais. O diagnóstico precoce e o tratamento adequado se fazem necessários a fim de prevenirem maiores danos aos portadores desta doença complexa sub diagnosticada. Neste contexto, as interferências medicamentosas são importantes achados nos exames laboratoriais que avaliam o DM e devem ser reconhecidas pelos profissionais de saúde envolvidos.
    Keywords Diabetes mellitus ; Reação Adversa a Medicamentos ; Técnicas e Procedimentos Diagnósticos ; Medicine ; R ; Pharmacy and materia medica ; RS1-441
    Language English
    Publishing date 2013-12-01T00:00:00Z
    Publisher Federal Council of Pharmacy
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top